Subclinical macular edema as a predictor of progression to clinically significant macular edema in type 2 diabetes

Ophthalmologica

Volumn 230, Issue 4, 2013, Pages 201-206

  Pires, Isabel ^a,b,c   Santos, Ana Rita ^a   Nunes, Sandrina ^a,c   Lobo, Conceição ^a,b,c   Cunha Vaz, José ^a  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Center point thickness; Clinically significant macular edema; Nonproliferative diabetic retinopathy; Optical coherence tomography; Subclinical diabetic macular edema; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EYE EXAMINATION; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PROSPECTIVE STUDY; RETINA MACULA EDEMA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ACUITY; CLINICALLY SIGNIFICANT MACULAR EDEMA; MACULAR EDEMA; MACULAR THICKNESS; OPHTHALMOLOGY; RETINAL THICKNESS;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84888269568     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000354550     Document Type: Article

References (15)

1. Paunescu LA, Schuman JS, Price LL, Stark PC, Beaton S, Ishikawa H, Wollstein G, Fujimoto JG: Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT. Invest Ophthalmol Vis Sci 2004; 45: 1716-1724. (Pubitemid 38868963)
2. Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C; Diabetic Retinopathy Clinical Research Network: Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007; 114: 1520-1525.
3. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM: Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004; 122: 330-335. (Pubitemid 38314192)
4. Browning DJ, Fraser CM, Clark S: The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology 2008; 115: 533-539.
5. Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK; Diabetic Retinopathy Clinical Research Network: Observational study of subclinical diabetic macular edema. Eye (Lond) 2012; 26: 833-840.
6. Sng CC, Cheung CY, Man RE, Wong W, Lavanya R, Mitchell P, Aung T, Wong TY: Influence of diabetes on macular thickness measured using optical coherence tomography: the Singapore Indian Eye Study. Eye (Lond) 2012; 26: 690-698.
7. Browning DJ, Fraser CM: The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol 2008; 145: 149-154.
8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806.
9. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98(5 suppl):741-756.
10. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network: Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol 2008; 145: 894-901.
11. Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH; MBDL and MBCU Study Groups: The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci 2013; 54: 1750-1757.
12. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC; PKC-DRS and PKC-DRS2 Study Groups: Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina 2011; 31: 2084-2094.
13. Lobo CL, Bernardes RC, Figueira JP, Faria de Abreu JR, Cunha-Vaz JG: Three-year followup of blood retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative retinopathy. Arch Ophthalmol 2004; 122: 211-217. (Pubitemid 38176488)
14. Cunha-Vaz J, Bernardes R, Lobo C: Bloodretinal barrier. Eur J Ophthalmol 2011; 21(suppl 6):S3-S9.
15. van Dijk HW, Verbraak FD, Kok PH, Stehouwer M, Garvin MK, Sonka M, DeVries JH, Schlingemann RO, Abramoff MD: Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 2012; 53: 2715-2719.